Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Wilding

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Trials|August 9, 2018
Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome setNicola L Harman, John Wilding, Dave Curry, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 25, 2018
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical PracticeJohn Wilding, Kevin Fernando, Nicola Milne, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 11, 2019
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into PracticeAmar Ali, Steve Bain, Debbie Hicks, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 30, 2020
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 DiabetesDavid C Wheeler, June James, Dipesh Patel, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 20, 2019
Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into PracticeAmar Ali, Steve Bain, Debbie Hicks, et al.
BMJ Open|February 16, 2020
Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trialDimitris Papamargaritis, Werd Al-Najim, Jonathan Lim, et al.
The Science of the Total Environment|October 31, 2018
Generation rate and fate of surplus soil extracted in New York CityDaniel Walsh, Isabel McRae, Ryan Zirngibl, et al.
Obesity (Silver Spring, Md.)|June 15, 2026
SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With ObesityMartin K Rutter, Julie Mount, J Martin Gibson, et al.
The Lancet. Diabetes & Endocrinology|August 8, 2024
Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementationJonathan Valabhji, Tessa Gorton, Emma Barron, et al.
Lancet (London, England)|October 15, 2018
Time for a new obesity narrativeJohanna Ralston, Hannah Brinsden, Kent Buse, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Trials|August 9, 2018
Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome setNicola L Harman, John Wilding, Dave Curry, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 25, 2018
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical PracticeJohn Wilding, Kevin Fernando, Nicola Milne, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 11, 2019
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into PracticeAmar Ali, Steve Bain, Debbie Hicks, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 30, 2020
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 DiabetesDavid C Wheeler, June James, Dipesh Patel, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 20, 2019
Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into PracticeAmar Ali, Steve Bain, Debbie Hicks, et al.
BMJ Open|February 16, 2020
Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trialDimitris Papamargaritis, Werd Al-Najim, Jonathan Lim, et al.
The Science of the Total Environment|October 31, 2018
Generation rate and fate of surplus soil extracted in New York CityDaniel Walsh, Isabel McRae, Ryan Zirngibl, et al.
Obesity (Silver Spring, Md.)|June 15, 2026
SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With ObesityMartin K Rutter, Julie Mount, J Martin Gibson, et al.
The Lancet. Diabetes & Endocrinology|August 8, 2024
Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementationJonathan Valabhji, Tessa Gorton, Emma Barron, et al.
Lancet (London, England)|October 15, 2018
Time for a new obesity narrativeJohanna Ralston, Hannah Brinsden, Kent Buse, et al.
Pageof 8